US8816242098
US8816242098
Teva Pharmaceutical Industries
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 47.93B EUR | 39.48B EUR | 35.07B EUR | 35.89B EUR |
Enterprise Value | 58.98B EUR | 52.7B EUR | 48.24B EUR | 49.42B EUR |
Valuation Multiples | ||||
Trailing P/E | 68.5x | 55.92x | 22.42x | 30.03x |
Forward P/E | 13.29x | -- | -- | -- |
Price to Sales | 2.77x | 2.28x | 2.02x | 2.68x |
Price to Book | 6.18x | 5.09x | 4.26x | 4.54x |
EV/Revenue | 3.41x | 3.04x | 2.78x | 3.7x |
EV/EBITDA | 13.82x | 12.49x | 9.77x | 12.51x |
Price to FCF (P/FCF) | 21.59x | 29.29x | 29.93x | 26x |
EV/FCF | 26.57x | 39.09x | 41.16x | 35.81x |
FCF Yield | 4.63% | 3.41% | 3.34% | 3.85% |